Gregory G. Schwartz, M male extra .D., Ph.D., Anders G. Olsson, M.D., Ph.D., Markus Abt, Ph.D., Christie M. Ballantyne, M.D., Philip J. Barter, M.D., Ph.D., Jochen Brumm, Ph.D., Bernard R. Chaitman, M.D., Ingar M. Holme, Ph.D., David Kallend, M.B., B.S., Lawrence A. Leiter, M.D., Eran Leitersdorf, M.D., John J.V. McMurray, M.D., Hardi Mundl, M.D., Stephen J. Nicholls, M.B., B.S., Ph.D., Prediman K. Shah, M.D., Jean-Claude Tardif, M.D., and R. Scott Wright, M.D. For
The 95 percent confidence interval for the hazard ratio is presented. Chi-square assessment was used for rate of recurrence comparisons. All reported subgroup analyses were prespecified. Periprocedural myocardial infarction was described in the protocol as a troponin level or a creatine kinase MB level 6 hours after the treatment that was more than 3 times the upper limit of the normal range.15 Prespecified sensitivity analyses using more stringent definitions of type 4a myocardial infarction were performed. All testing had a two-sided significance level of 5 percent and were performed with the use of SAS software, version 9.2 . Results Features of the Patients From 2009 through January 2011 January, we enrolled 2440 individuals, of whom 1227 were assigned to the conventional-treatment group and 1213 to the monitoring group .